5.3
Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients
5.4 Risk of HIV-1 Resistance Development
Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection
https://www.fda.gov/media/155050/download
5.3 Hepatic transaminase elevations, clinical hepatitis, and jaundice have occurred in patients receiving ritonavir. Therefore, caution should be exercised when administering PAXLOVID to patients
5.4 Risk of HIV-1 Resistance Development Because nirmatrelvir is co-administered with ritonavir, there may be a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection
https://en.wikipedia.org/wiki/Ritonavir
https://news.yahoo.com/gov-gavin-newsom-tests-positive-014816621.html
https://www.theatlantic.com/health/archive/2022/05/paxlovid-covid-rebound-pfizer-clinical-trials/638438/
https://www.reuters.com/business/healthcare-pharmaceuticals/us-doctors-reconsider-pfizers-paxlovid-lower-risk-covid-patients-2022-05-28/
https://www.nytimes.com/live/2022/05/26/world/covid-19-mandates-vaccine-cases